City of Hope/LinkedIn
May 10, 2025, 09:40
Promising New Drug Combination for Colon Cancer Resistant to Standard Treatments
City of Hope shared a post on LinkedIn:
“A Phase 3 clinical trial shows promise for patients with KRAS G12C metastatic colorectal cancer no longer responding to chemotherapy.
Dr. Marwan Fakih published a study in the Journal of Clinical Oncology which found that combining sotorasib and panitumumab significantly prolongs survival compared to standard care. Over 30% of patients who received the higher dose saw their tumors reduced by more than half, versus just 1.9% with standard care.
The exciting results of this combination therapy suggest that it might become the new standard of care for this disease.
More posts featuring Colon Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 10, 2025, 09:40
May 10, 2025, 09:20
May 10, 2025, 08:41